TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations

Condition studied

Interstitial Lung Disease

Investigational medicinal product(s)

Every trial of Azithromycin, Hydroxychloroquine, Prednisolone and Prednisone across our registers →

Eligibility

Primary endpoint

Difference in forced vital capacity decline between the 2 groups at one year

Endpoint detail

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization), Thoracic CT scan and PFT at 6 months and one year after randomization, Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,, Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization